South San Francisco, CA ; 3/3/20
Amount Funded: $100 Million
Type: Series C
Lead Investor: Novartis
Participating Investor(s): Redmile Group, Farallon Capital Mgmt. , Cormorant Asset Mgmt., Surveyor Captial, Logos Capital (new investors); Agent Capital, Cowen Healthcare Investments, Schroder Adveq, SCubed Capital, Menlo Ventures, undisclosed institutional investors
Company Description: Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel targeted therapies to slow or halt the progression of multiple life-threatening fibrotic diseases.
What funding will be used for: Supporting the continued clinical development of therapies for fibrotic diseases and continuing ongoing discovery programs for fibrotic diseases.
“Our team is proud to have the support and strategic expertise provided by this group of world-class investors to help us achieve our vision of developing transformative medicines for patients living with devastating fibrotic diseases.This financing will support the continued clinical development of our lead product candidate in IPF and PSC, as well as our continued strategy to build our pipeline of proprietary product candidates for a wide range of other fibrotic diseases.”
-Bernard Coulie, M.D., Ph. D., President and CEO, Pliant Therapeutics
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.